Volrustomig
ASTRAZENECA PLC AZN · Locally Advanced Cervical Cancer; Locally Advanced Head and Neck Squamous Cell Carcinoma; Metastatic Non-small Cell Lung Cancer; Unresectable Pleural Mesothelioma
Key figures
Next catalyst
None scheduled
Only dates with a source are listed
Phase
Phase 3
Not recorded
Linked trials
4
From ClinicalTrials.gov
Latest FDA action
None on record
From Drugs@FDA
Recalls, shortages, patents and EU status at a glance
Key information
- Sponsor
- ASTRAZENECA PLC AZN Source: Company record for ASTRAZENECA PLC (opens in a new tab)
- Indications
- Locally Advanced Cervical Cancer; Locally Advanced Head and Neck Squamous Cell Carcinoma; Metastatic Non-small Cell Lung Cancer; Unresectable Pleural Mesothelioma Source: Conditions from ClinicalTrials.gov (opens in a new tab)
- Designations
- None recorded
- Next catalyst
- None scheduled
Development timeline
- Preclinical Completed
- Phase 1 Completed
- Phase 2 Completed
- Phase 3 Current stageFirst trial start 22 Sep 20234 linked trials
- Filed Not yet
- Approved Not yet
Overview
- Mechanism
- Not recorded
- Route
- Not recorded
- Modality
- Not recorded
- Specialties
- Not recorded
Overview text is written by HealthTrade editors.
Key dates
No catalysts yet. Editors add each date together with its source.
FDA designations
No FDA designations are on record for Volrustomig. Editors add each one with its source.
Filed application
No filed application is on record for Volrustomig. Approvals are listed under FDA actions.
FDA advisory committees
No FDA advisory committee meetings are on record for Volrustomig.
Clinical trials
| Trial | Title | Phase | Status | Enrollment | Primary completion | Results posted |
|---|---|---|---|---|---|---|
| NCT06129864ClinicalTrials.gov record for NCT06129864 (opens in a new tab)eVOLVE-HNSCC | A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy | Phase 3 | Recruiting | 1,145 (estimated) | 17 Apr 2030 (estimated) | No |
| NCT06097728ClinicalTrials.gov record for NCT06097728 (opens in a new tab)eVOLVE-Meso | MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma | Phase 3 | Active, not recruiting | 863 (actual) | 16 Nov 2028 (estimated) | No |
| NCT05984277ClinicalTrials.gov record for NCT05984277 (opens in a new tab)eVOLVE-Lung02 | A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. | Phase 3 | Active, not recruiting | 895 (actual) | 17 Aug 2026 (actual) | No |
| NCT06079671ClinicalTrials.gov record for NCT06079671 (opens in a new tab)eVOLVECervical | Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) | Phase 3 | Recruiting | 800 (estimated) | 26 Nov 2027 (estimated) | No |
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Posted results are shown as ClinicalTrials.gov prints them; results from company and journal sources are entered by editors and listed separately. Full result tables are on ClinicalTrials.gov.
Trial quality
About CT-VCALoading trial quality…
FDA actions
No FDA approvals on record for this drug.
FDA recalls load here.
FDA drug shortages load here.
Orange Book patents load here.
FAERS adverse event counts load here.
Papers and preprints load here.
Community discussion loads here.
EU status (EMA)
EMA's medicines data lists no human medicine with the same active substance as Volrustomig.
Source: European Medicines Agency (EMA), medicines data download.
Related news
No recent headlines mention this drug.
Sources
- ClinicalTrials.gov NCT06129864 (opens in a new tab) Licence: public-domain. Official registry record this listing came from
- ClinicalTrials.gov NCT06097728 (opens in a new tab) Licence: public-domain. Official registry record this listing came from
- ClinicalTrials.gov NCT06079671 (opens in a new tab) Licence: public-domain. Official registry record this listing came from
- ClinicalTrials.gov NCT05984277 (opens in a new tab) Licence: public-domain. Official registry record this listing came from
Record updated .
Dates come from company and FDA disclosures and can change. Nothing on this page is investment advice.